New Spryng Study Reports Improvement in Dogs With Knee Joint Pain and Osteoarthritis

Peer-reviewed veterinary study finds 55% of dogs achieved at least a 25% improvement in the main pain score after a single joint injection

MINNEAPOLIS, July 14, 2026: A new peer-reviewed veterinary study has reported encouraging short-term results for dogs with knee joint osteoarthritis and suspected cranial cruciate ligament disease.

The study evaluated Spryng with OsteoCushion Technology, a veterinary joint injection developed by PetVivo Holdings. The research has been published in Veterinary Record study abstract, a peer-reviewed veterinary journal.

40 dogs followed for 84 days

The study included 40 privately owned dogs with suspected disease in one knee joint and osteoarthritis. Each dog received a single injection of collagen and elastin-based particles directly into the affected joint.

The dogs were then followed for 84 days. Veterinarians and pet owners assessed pain and clinical improvement at set time points.

55% of dogs reached the main improvement target

The key result was simple: 22 of the 40 dogs, or 55%, showed at least a 25% improvement in the main pain score used by the researchers.

The study also reported statistically significant improvement in all the other measures based on veterinarian and owner assessments.

These results suggest the treatment deserves further clinical investigation.

What is Spryng with OsteoCushion Technology?

Spryng is a veterinary medical device injected directly into an affected joint.

It contains tiny particles made from collagen and elastin, natural materials found in body tissues. The product is designed to provide support and cushioning inside the joint and is used by veterinarians to help manage lameness and joint problems in dogs, cats and horses.

Unlike a daily oral medicine, Spryng is administered by a veterinarian into the joint.

Dog cruciate disease is a major cause of pain and lameness

The cranial cruciate ligament plays an important role in stabilising a dog’s knee joint. Damage to this ligament can cause pain, limping and joint instability. Osteoarthritis can also develop or worsen as the joint changes over time.

Managing these dogs can involve weight control, pain medicines, rehabilitation and, in suitable cases, surgery.

The growing interest in joint injections reflects demand for additional ways to manage canine pain and mobility.

Important limitations: this was a small early study

The results need to be viewed carefully. The researchers clearly reported several limitations. The study had no control group, no random treatment allocation and no blinding. It also did not use objective measurements of lameness, and suspected cruciate disease was not confirmed surgically.

This matters because owner and veterinarian assessments can be influenced by expectations. The researchers therefore described the work as a proof-of-concept study and called for further research using objective measurements.

Why the Spryng dog joint study matters

Despite its limitations, the publication is important for PetVivo because it adds peer-reviewed clinical evidence around Spryng. The company says this is now the third peer-reviewed scientific publication evaluating Spryng with OsteoCushion Technology.

For the wider veterinary industry, the study also highlights growing investment in new treatments for dog osteoarthritis, joint pain and mobility problems.

The headline result is encouraging: 55% of dogs reached the study’s main pain improvement target. However, larger controlled studies with objective measures of movement and lameness are still needed before stronger conclusions can be made.